1-butyl-3-(prop-2-ynyl)urea | 155453-04-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-butyl-3-(prop-2-ynyl)urea
• 英文别名: 1-butyl-3-(prop-2-yn-1-yl)urea；1-Butyl-3-prop-2-ynylurea
• CAS: 155453-04-6
• 化学式: C₈H₁₄N₂O
• mdl: MFCD14631464
• 分子量: 154.212
• InChiKey: YOMXZTXWEGCUAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-butyl-3-(prop-2-ynyl)urea 在 三乙胺 、 二溴三苯基膦 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  使用“点击”和Sonogashira反应的炔烃官能化螺旋聚碳二亚胺的合成及其与小分子的连接

  摘要：

  已经合成了新的末端炔烃侧链官能化的聚碳二亚胺，并利用“炔烃”连接工具（“点击”（铜催化的惠斯根1,3-偶极环加成反应）和Sonogashira偶联在一步聚合后改性中制备了功能聚合物。聚碳二亚胺是有趣的合成，螺旋，纳米尺度的支架，能够以高度规则的周期性方式呈现各种官能团。在这里，我们报道了第一个炔烃取代的聚碳二亚胺，Poly-1，Poly-2和Poly-3的合成，以及功能叠氮化物与这些聚合物的炔烃重复单元的定量偶联，如IR和1 H NMR和131 H NMR谱。我们通过“点击”和能够耦合苄基叠氮化物，羧酸叠氮化物，和N-Boc胺叠氮化物Ñ -Boc-升通过薗头反应的炔侧链-苯丙氨酸聚1，以提供聚1A，-1b，-1c和-1phe。聚- 1B和聚-1C提供肽的偶合部位，并且是合成的螺旋高分子-肽缀合物的前体。通过将1-丙氨酸甲酯与Poly-1b偶联以优异的转化率证明了这一点。脂族末端炔烃官能化聚

  DOI：

  10.1021/ma200960e
• 作为产物：
  描述：

  2-丙炔-1-基氨基甲酸苄酯 、 正丁胺 在 lanthanum(lll) triflate 作用下， 反应 12.0h， 以77%的产率得到1-butyl-3-(prop-2-ynyl)urea
  参考文献：
  名称：

  三氟甲磺酸镧 (III) 催化从 N-苄氧羰基-、N-烯丙氧羰基-和 N-2,2,2-三氯乙氧羰基保护的胺直接合成脲

  摘要：

  发现了一种新型三氟甲磺酸镧介导的 N-苄氧羰基-、N-烯丙氧羰基-和 N-三氯乙氧羰基-保护的胺转化为非对称脲。在这项研究中，发现三氟甲磺酸镧是一种从受保护的胺制备各种非对称脲的有效催化剂。在三氟甲磺酸镧存在下，各种受保护的芳香族和脂肪族氨基甲酸酯很容易与各种胺反应，以高产率生成所需的尿素。该结果表明，这种由 Cbz、Alloc 和 Troc 氨基甲酸酯催化制备尿素的新型三氟甲磺酸镧可用于形成各种尿素结构。

  DOI：

  10.1055/s-0040-1707991

文献信息

• Unexpected Stereoselective Access to 2‐Aminooxazolines from Propargyl Ureas by Silver Salts under Mild Conditions
  作者：Aleksandr Voronov、Alessandra Casnati、Paolo P. Mazzeo、Paolo Pelagatti、Alessia Bacchi、Raffaella Mancuso、Bartolo Gabriele、Elena Motti、Giovanni Maestri、Péter Pál Fehér、András Stirling、Nicola Della Ca'

  DOI：10.1002/adsc.202200950

  日期：——

  Propargyl ureas can lead to a range of possible heterocyclic compounds, mainly depending on the employed catalyst. Silver salts are known to promote the N-5-exo-dig cyclization mode to imidazolidinone derivatives. Conversely, a versatile and stereoselective O-5-exo-dig cyclization of propargyl ureas to 2-aminooxazolines by Ag(I) catalysis is here disclosed. Good to excellent yields and complete stereoselectivity

  炔丙基脲可导致一系列可能的杂环化合物，主要取决于所使用的催化剂。已知银盐促进N -5 -exo-dig环化模式生成咪唑啉酮衍生物。相反，此处公开了通过 Ag(I) 催化将炔丙基脲生成 2-氨基恶唑啉的多功能和立体选择性O -5-外切环化。在较温和的反应条件 (50–60 °C) 下，已经实现了良好到极好的收率和外部双键的完全立体选择性。还开发了从相应的炔丙基胺和异氰酸酯开始的一锅法方案。N , N '-二炔丙基脲经历了罕见的O-5- exo-dig/N -5 -endo-dig双环化序列。最后，提供了对 2-氨基恶唑的互变异构平衡及其相对反应性的见解。
• Aliphatic prolinamide derivatives
  申请人：ORION OPHTHALMOLOGY LLC

  公开号：US10730832B2

  公开（公告）日：2020-08-04

  This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

  本发明涉及式I的新型脂肪族丙氨酰胺衍生物及其药学上可接受的盐、溶液剂、盐的溶解物和原药，可用于预防（如延缓发病或降低发病风险）和治疗（如控制、减轻或延缓进展）老年性黄斑变性（AMD）及相关眼部疾病。这些疾病包括干性黄斑变性、湿性黄斑变性、地理萎缩、糖尿病视网膜病变、早产儿视网膜病变、多形性脉络膜血管病变以及视网膜或感光细胞变性。本文公开的本发明进一步涉及预防、减缓干性-AMD、湿性-AMD 和地理萎缩、糖尿病视网膜病变、早产儿视网膜病变、多形性脉络膜血管病变以及视网膜或感光细胞变性的进展和治疗方法，包括：施用治疗有效量的本发明化合物。本发明化合物是 HTRA1 的抑制剂。因此，本发明化合物可用于预防和治疗由 HTRA1（全部或部分）介导的多种疾病。本发明的化合物还可用于抑制关节炎或相关疾病的眼部或病灶中的 HTRA1 蛋白酶活性。
• PREZIOS, ANTHONY F.;PRUSIK, THADDEUS
  作者：PREZIOS, ANTHONY F.、PRUSIK, THADDEUS

  DOI：——

  日期：——
• ALIPHATIC PROLINAMIDE DERIVATIVES
  申请人：ORION OPHTHALMOLOGY LLC

  公开号：US20190330146A1

  公开（公告）日：2019-10-31

  This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.
• Lanthanum(III) Trifluoromethanesulfonate Catalyzed Direct Synthesis of Ureas from N-Benzyloxycarbonyl-, N-Allyloxycarbonyl-, and N-2,2,2-Trichloroethoxycarbonyl-Protected Amines
  作者：Hee-Kwon Kim、Tien Tan Bui

  DOI：10.1055/s-0040-1707991

  日期：2020.6

  A novel lanthanum triflate mediated conversion of N-benzyl­oxycarbonyl-, N-allyloxycarbonyl-, and N-trichloroethoxycarbonyl-­protected amines into nonsymmetric ureas was discovered. In this study, lanthanum triflate was found to be an effective catalyst for preparing various nonsymmetric ureas from protected amines. A variety of protected aromatic and aliphatic carbamates reacted readily with various

  发现了一种新型三氟甲磺酸镧介导的 N-苄氧羰基-、N-烯丙氧羰基-和 N-三氯乙氧羰基-保护的胺转化为非对称脲。在这项研究中，发现三氟甲磺酸镧是一种从受保护的胺制备各种非对称脲的有效催化剂。在三氟甲磺酸镧存在下，各种受保护的芳香族和脂肪族氨基甲酸酯很容易与各种胺反应，以高产率生成所需的尿素。该结果表明，这种由 Cbz、Alloc 和 Troc 氨基甲酸酯催化制备尿素的新型三氟甲磺酸镧可用于形成各种尿素结构。